DoD funds Tiziana Life Sciences (TLSA) study of intranasal anti-CD3 in spinal cord injury

Rhea-AI Filing Summary

Tiziana Life Sciences LTD reported that the U.S. Department of Defense has awarded a research grant to study its intranasal anti-CD3 therapy in traumatic spinal cord injury. This program aims to evaluate whether the company’s intranasal anti-CD3 platform, previously focused on autoimmune and neuroinflammatory diseases, can be applied to severe neurological trauma such as spinal cord injury. The grant supports Tiziana’s strategy to expand this platform into larger, underserved neurological indications, potentially broadening the future scope of its therapeutic pipeline.

Insights

Biotech and healthcare equity analyst

DoD grant supports Tiziana’s intranasal anti-CD3 in spinal cord injury.

The U.S. Department of Defense has awarded a research grant to study Tiziana Life Sciences LTD’s intranasal anti-CD3 therapy in traumatic spinal cord injury. This explicitly links a U.S. government research program with the company’s existing intranasal anti-CD3 platform, which has been focused on autoimmune and neuroinflammatory diseases.

The initiative aligns with the company’s strategy to expand this platform into large, underserved neurological indications. While the size or duration of the grant is not stated in the excerpt, association with a Department of Defense–funded study can help validate clinical interest in the approach and extend its potential application to severe neurological trauma.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 09/15/2025 - 08:00 AM Learn about SEC filing dates

FAQ

What did Tiziana Life Sciences (TLSA) announce in this 6-K?

Tiziana Life Sciences LTD announced that the U.S. Department of Defense has awarded a research grant to study its intranasal anti-CD3 therapy in traumatic spinal cord injury.

What therapy from Tiziana Life Sciences (TLSA) is involved in the new grant?

The grant focuses on Tiziana’s intranasal anti-CD3 therapy, a platform the company has been developing for autoimmune and neuroinflammatory diseases.

What condition will Tiziana Life Sciences (TLSA) study with the DoD grant?

The research grant supports a study of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI), a severe neurological condition.

How does this grant fit Tiziana Life Sciences (TLSA)’s strategy?

The grant builds on Tiziana’s strategy to expand the therapeutic potential of its intranasal anti-CD3 platform beyond autoimmune and neuroinflammatory diseases into large, underserved neurological indications.

Is the Tiziana Life Sciences (TLSA) DoD grant information part of the company’s filed financial statements?

The company states that the attached press release in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor automatically incorporated by reference into other filings.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 15, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing that the U.S. Department of Defense (DoD) have awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). This funding builds on Tiziana’s strategy to expand the therapeutic potential of its intranasal anti-CD3 platform beyond autoimmune and neuroinflammatory diseases into large, underserved neurological indications.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: September 15, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated September 15, 2025

3